Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report

Abstract

Palmoplantar psoriasis, a clinical variant of plaque psoriasis, has a significant impact by causing deterioration in the social and functional aspects of patients’ lives. Numerous therapeutic interventions are available for palmoplantar psoriasis. Although emerging biological agents have had an enormous positive impact on chronic plaque psoriasis, studies assessing their effectiveness in the palmoplantar phenotype are limited in the literature. We therefore present a case report of a patient with a 10-year history of palmoplantar psoriasis, which has significantly impacted her occupational life. She was treated with Risankizumab, showing a significant and rapid improvement in her symptoms. We believe that Risankizumab could be one of the most effective therapeutic interventions in the clinical context where rapid clearance of palmoplantar psoriasis is required.

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience

“…In fact, whilst previous treatments had proved largely ineffective, risankizumab induced a rapid improvement in PP as well as in concomitant plaques psoriasis in these patients. This rapidity of action is consistent with some previously published cases 10 , 11 that reported an almost complete clearance of PP even after the first two drug injections. Similar data were also reported by Megna et al, who compared the efficacy of guselkumab, risankizumab and tildrakizumab in a 28-week retrospective study.…”